Clinical trial outcomes posted recently in The New England Journal of Medicine showed that, reached individuals who brought a placebo, those carrying semaglutide had 24% lower odds of having a significant kidney infection event, such as requiring dialysis, obtaining a kidney transplant, failing at least half of their kidney operation, or breaking from kidney-related or cardiovascular reasons. The trial contained about 3,500 individuals with kidney disorders and type 2 diabetes.

Another recent study that had 17,600 individuals who were obese or fat and who had cardiovascular conditions discovered that 22% more periodic people participated in kidney-related circumstances in a group obtaining a weekly semaglutide injection reached with a group taking a placebo.

The analyses indicate that semaglutide displays a vow for dining chronic kidney condition, which happens when the kidneys become impaired and slowly lose the capacity to screen blood the way they should. More than one in seven grown-ups in the United States has the disease, which has no treatment.

As it stands, the Food and Drug Administration has agreed on Wegovy for weight control and Ozempic to allow control of type 2 diabetes. After students found that the drugs decreased the chance of significant negative cardiovascular occasions by 20%, the FDA also supported them in lowering the chances of cardiovascular end, heart attack, and stroke in adults with cardiovascular illness and overweight or obese.

However, students have not only seen that Ozempic and Wegovy—which belong to a class of medications named glucagon-like peptide-1 (GLP-1) receptor agonists—may have the possibility to save kidney fitness, but that the drugs may also have the possibility to curb a slew of other shapes.

“Obesity is associated with more than 200 comorbidities,” Priya Jaisinghani, MD, a clinical associate lecturer at NYU Grossman School of Medicine in New York City, told Health. “Precluding and curing of obesity will recreate a role in precluding, reverse, or remission of such comorbidities.”

Here are some other conditions that the study shows semaglutide may enhance or decrease the risk of an individual setting.


Investigations have indicated that people with type 2 diabetes who take GLP-1 receptor agonists, such as semaglutide, may have a lower speed of dementia compared to individuals given a placebo.

Because of this, students have begun attempts to assess how the drug affects individuals with early Alzheimer’s illness. 

One way that semaglutide might reduce an individual’s risk of Alzheimer’s is by enhancing diabetes, a risk element for dementia.

According to the Alzheimer’s Association, diabetes increases the gamble of heart disease, which impairs blood vessels, including those in the brain. Impaired blood vessels may contribute to the growth of Alzheimer’s. Too much sugar in the blood can also induce rash, which can also cause harm to the brain.


Research delivered June 1 at the Endocrine Society’s conference in Boston revealed that semaglutide may reduce the risk of acute pancreatitis, the rash inflammation of the pancreas.

Researchers calculated what occurred when 638,501 individuals with a history of pancreatitis took either no drug, semaglutide, or other medicines for diabetes and obesity reached SGLT2 inhibitors and DPP4s.

Within 15 years of creating semaglutide, 15% of players set pancreatitis again, reached 24% who took SGLT2 inhibitors, 23% on DPP4s, and almost 52% of individuals not carrying medicine.

Import Dependence

A small study issued in 2023 indicated that semaglutide may reduce signs of alcohol use condition, which affects issues restricting alcohol intake.

“GLP-1s seem to alter some of the passion and bonus drive in the brain, and we don’t fully comprehend how that’s occurring at this point,” Jesse Richards, DO, an inner medicine doctor at the University of Oklahoma, who led the investigation, told Health. “There appears to be a reduction in the desires or the reason to pursue.”

The study was only a “case string” study, which suggests it’s not robust enough to attract broad findings. Regardless, Richards stated he’s conducting a randomized collected trial to monitor alcohol use in individuals on semaglutide or a placebo, with effects anticipated next year.

Polycystic Syndrome

Semaglutide is utilized off-label—meaning it’s stipulated by physicians for a non-FDA authorized purpose—to treat signs of (PCOS), a hormone inequality that usually happens when an individual has high-than-normal groups of androgens. The disease involves the ovaries, causing them to create numerous small cysts.

Anecdotal proof and some small investigations indicate that semaglutide may be useful for individuals with PCOS.

Many individuals with PCOS are heavy or obese and may have insulin opposition, prediabetes, or diabetes, Marilyn Tan, MD, director of the Endocrine Clinic at Stanford University School of Medicine, told Health.

“With consequence loss and enhanced glucose management, menstrual cycles may evolve more common, and sometimes hyperandrogenism (excess hair, acne) may enhance,” Tan stated.

However, randomized trials are required to ensure semaglutide’s positive impact on PCOS, she counted.


Leave a Reply

Your email address will not be published. Required fields are marked *